ZETACOLEST tablets, for oral use, contain :
The active substance is bempedoic acid. Each film-coated tablet contains 180 mg of bempedoic acid.
Indications and usage:
ZETACOLEST is indicated:
• To reduce the risk of myocardial infarction and coronary revascularization in adults who are
unable to take recommended statin therapy (including those not taking a statin) with:
established cardiovascular disease (CVD), or
a high risk for a CVD event but without established CVD.
• As an adjunct to diet, in combination with other low-density lipoprotein cholesterol (LDL-C)
lowering therapies, or alone when concomitant LDL-C lowering therapy is not possible, to
reduce LDL-C in adults with primary hyperlipidemia, including heterozygous familial
hypercholesterolemia (HeFH).
Storage and handling :
Carton Box containing 1,2 or 3 Strips (AL\AL), each of 10 Film Coated Tablets and inner leaflet.
|